HFB-200301 is a monoclonal IgG1 antibody specifically designed to target tumor necrosis factor receptor 2 (TNFR2). This antibody facilitates the activation of TNFR2, which in turn initiates the classical NF-κB signaling pathway, involving the activation of RelA and cRel-containing NF-κB dimers. This activation impacts cellular metabolism and gene expression in response to soluble TNF (sTNF). HFB-200301 holds significant potential for advancing research in cancer biology, particularly in studies exploring the molecular mechanisms of TNFR2 in tumor progression and immune responses.
HFB-200301 is a monoclonal IgG1 antibody specifically designed to target tumor necrosis factor receptor 2 (TNFR2). This antibody facilitates the activation of TNFR2, which in turn initiates the classical NF-κB signaling pathway, involving the activation of RelA and cRel-containing NF-κB dimers. This activation impacts cellular metabolism and gene expression in response to soluble TNF (sTNF). HFB-200301 holds significant potential for advancing research in cancer biology, particularly in studies exploring the molecular mechanisms of TNFR2 in tumor progression and immune responses.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
